Pivotal readout

Innovent's tafolecimab lowers LDL-C about 65% as first-line monotherapy in Phase 3

In the 198-patient CREDIT-5 trial, Sintbilo given alone as first-line therapy met its week-12 primary endpoint, cutting LDL cholesterol by roughly 64% to 65%. No serious or severe adverse events, and none leading to discontinuation, were reported. Innovent plans to file the new indication with China's drug regulator soon.

Written by Gosset from public sources. Source types: Press release · News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call